JAMA Network Home
Sign In
Original Investigation

Azelastine Nasal Spray for Prevention of SARS-CoV-2 Infections

JAMA Internal Medicine 10.1001/jamainternmed.2025.4283

September 02, 2025 at 11:00 AM EDT

Read the full article

Is regular application of azelastine nasal spray associated with reduced risk of SARS-CoV-2 infections?In this randomized placebo-controlled clinical trial that included 450 participants, the incidence of laboratory-confirmed SARS-CoV-2 infections was significantly lower with application of azelastine nasal spray compared with placebo treatment.The use of azelastine nasal spray may help to reduce the risk of SARS-CoV-2 infections.

Corresponding Author: Robert Bals, MD, PhD, Department of Internal Medicine V–Pulmonology, Allergology, Infectious Diseases, Intensive Care Medicine, Saarland University, Medical Center, 66421 Homburg Saar, Germany (robert.bals@uks.eu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2025.4283?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=090225

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks